GoAI
Get started
NewGenIvf Group Limited logo

NewGenIvf Group Limited

NIVF

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$0.5815

+$0.0248 · +4.45%

Aug 21, 4:00 PM ET

NIVF company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

91

Deep Value

Momentum

17

Strong Down

Sentiment

63

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Operating out of its headquarters in Bangkok, Thailand, NewGenIvf Group Limited specializes in delivering assisted reproductive services. The firm is committed to fulfilling the desire for family through a variety of fertility treatments. Its extensive service portfolio includes conventional in-vitro fertilization (IVF), egg donation, and surrogacy, all complemented by comprehensive ancillary care.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
TH
CEO
Wing Fung Siu
Listed since
Mar 18, 2022
Employees
87

Market position

Day range

Current $0.5815

52-week range

Current $0.5815

Open
$0.58
Previous close
$0.5567
Volume
179.56K
0.12× average
Average volume
1.56M
Average daily volume
Market cap
110.2K USD
Beta
-0.04
Market reference 1
50-day average
$1.2116
-52.01% below average
200-day average
$16.0423
-96.38% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
0.01×
P/B (TTM)
0×
P/S (TTM)
0.04×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
23.72%
Operating margin
-276.57%
Net margin
338.20%

Financial health

Debt / equity
0.18×
Altman Z-score
1.71
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends253%78%-96%-271%Gross margin, FY2021: 24.89%Gross margin, FY2022: 25.87%Gross margin, FY2023: 32.74%Gross margin, FY2024: 33.63%Gross margin, FY2025: 20.22%Operating margin, FY2021: 4.83%Operating margin, FY2022: 6.71%Operating margin, FY2023: 0.82%Operating margin, FY2024: -21.35%Operating margin, FY2025: -226.95%Net margin, FY2021: -0.01%Net margin, FY2022: 7.72%Net margin, FY2023: 2.53%Net margin, FY2024: -9.66%Net margin, FY2025: 209.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 24.89%. Gross margin FY2022 25.87%. Gross margin FY2023 32.74%. Gross margin FY2024 33.63%. Gross margin FY2025 20.22%. Operating margin FY2021 4.83%. Operating margin FY2022 6.71%. Operating margin FY2023 0.82%. Operating margin FY2024 -21.35%. Operating margin FY2025 -226.95%. Net margin FY2021 -0.01%. Net margin FY2022 7.72%. Net margin FY2023 2.53%. Net margin FY2024 -9.66%. Net margin FY2025 209.02%.

Income trends

Revenue

4.73M USD-13.01%

Operating income

−10.73M USD-824.69%

Net income

9.88M USD+10.4M USD
Income trends across reported periods11.94M USD3.7M USD−4.54M USD−12.79M USDRevenue, FY2021: 4.12M USDRevenue, FY2022: 5.94M USDRevenue, FY2023: 5.14M USDRevenue, FY2024: 5.43M USDRevenue, FY2025: 4.73M USDOperating income, FY2021: 198.76K USDOperating income, FY2022: 398.71K USDOperating income, FY2023: 42.24K USDOperating income, FY2024: −1.16M USDOperating income, FY2025: −10.73M USDNet income, FY2021: −533 USDNet income, FY2022: 458.67K USDNet income, FY2023: 130.19K USDNet income, FY2024: −525K USDNet income, FY2025: 9.88M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.12M USD. Revenue FY2022 5.94M USD. Revenue FY2023 5.14M USD. Revenue FY2024 5.43M USD. Revenue FY2025 4.73M USD. Operating income FY2021 198.76K USD. Operating income FY2022 398.71K USD. Operating income FY2023 42.24K USD. Operating income FY2024 −1.16M USD. Operating income FY2025 −10.73M USD. Net income FY2021 −533 USD. Net income FY2022 458.67K USD. Net income FY2023 130.19K USD. Net income FY2024 −525K USD. Net income FY2025 9.88M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.73M USD5.43M USD5.14M USD5.94M USD4.12M USD
Cost of goods sold3.77M USD3.61M USD3.45M USD4.41M USD3.09M USD
Gross profit955.85K USD1.83M USD1.68M USD1.54M USD1.03M USD
Selling, general, and administrative11.68M USD2.99M USD1.64M USD1.14M USD826.02K USD
Operating expenses11.68M USD2.99M USD1.64M USD1.14M USD826.02K USD
Interest income2.25K USD6.95K USD518 USD21 USD63 USD
Interest expense616.42K USD778.66K USD46.18K USD77.76K USD88.29K USD
Depreciation and amortization499.5K USD206.26K USD229.71K USD303.94K USD342.54K USD
Operating income−10.73M USD−1.16M USD42.24K USD398.71K USD198.76K USD
Net income9.88M USD−525K USD130.19K USD458.67K USD−533 USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 1 miss, 0 met estimates
Average EPS surprise
-98.90%
1 comparable report
Latest EPS result
1.53
Estimate 139.05 · Miss by 98.90%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates150.05100.4750.881.3Q4 '25No estimateQ2 '26MissQ3 '26Estimate
Q4 2025, reported Oct 9, 2025: actual 4.55, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 1, 2026: actual 1.53, estimate 139.05, surprise -98.90%, Miss. Q3 2026, reported Sep 2, 2026: actual —, estimate 6.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates21.55M14.94M8.33M1.72MQ4 '25No estimateQ2 '26MissQ3 '26Estimate
Q4 2025, reported Oct 9, 2025: actual 2.02M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 1, 2026: actual 2.71M USD, estimate 2.87M USD, surprise -5.78%, Miss. Q3 2026, reported Sep 2, 2026: actual —, estimate 20.1M USD, surprise —, Comparison unavailable.

NIVF news

globenewswire.com

NewGenIVF Completes Exchange of Convertible Notes with Institutional Investor

BANGKOK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today announced that it has completed an exchange agreement…

Read source
globenewswire.com

NewGen Provides Update on K25.ai Investment and Strengthened Financial Position

NewGen's total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen's agreed 13% stake in K25.ai is now valued at approximately US$26…

Read source
globenewswire.com

NewGen to Acquire Additional 3% of K25.ai at US$250 Million Valuation Following Strong Community Beta; Strengthening Market Cap Above US$5 Million

Follow-on investment would increase NewGen's aggregate ownership to 13% Follow-on investment would increase NewGen's aggregate ownership to 13%

Read source
globenewswire.com

NewGen's Strategic Pre-A Investment in K25.ai Doubles in Value as K25.ai's Valuation Reaches US$200 Million

K25.ai closes Series A investment round, reaching a post-money valuation of US$200 million NewGen's 10% ownership stake in K25.ai has reached US$20 million in value and generated a ~US$10 million unrealized gain,…

Read source
prnewswire.com

K25.ai Secures Series A Investment with Strategic Support from Amber Group, Valuation Doubles to US$200 Million

/PRNewswire/ -- K25.ai, the AI-native prediction market transforming livestreams into real-time interactive markets, today announced the closing of its Series

Read source
globenewswire.com

NewGen's Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million

Midpoint equity value for planned UAE cell sorting entity highlights significant growth runway in high-infertility, medical-tourism hotspot

Read source

NIVF peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NIVF

research.disclaimer